Long-term efficacy of ustekinumab and absolute PASI response in patients with moderate-to-severe psoriasis in a dermatology department of a university hospital

doi:10.1016/j.jaad.2017.06.147

Long-term efficacy of ustekinumab and absolute PASI response in patients with moderate-to-severe psoriasis in a dermatology department of a university hospital

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.06.147 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB426

Keyword(s):

Severe Psoriasis ◽

University Hospital ◽

Dermatology Department ◽

Term Efficacy

Download Full-text

Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.03.027 ◽

2018 ◽

Vol 79 (4) ◽

pp. 758-760 ◽

Cited By ~ 2

Author(s):

Abdallah Khemis ◽

Awatef Kelati ◽

Henri Montaudié ◽

Jean-Philippe Lacour ◽

Thierry Passeron

Keyword(s):

Retrospective Study ◽

Successful Treatment ◽

Severe Psoriasis ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Term Efficacy ◽

Receptor Inhibitor

Download Full-text

Cost-effectiveness of maintenance treatment for 1 year with biologic drugs for moderate to severe psoriasis in the dermatology department of a university hospital

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.691 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB166

Keyword(s):

Cost Effectiveness ◽

Maintenance Treatment ◽

Severe Psoriasis ◽

University Hospital ◽

Biologic Drugs ◽

Dermatology Department

Download Full-text

Long-term efficacy of tildrakizumab in patients with moderate to severe psoriasis who were nonresponders or partial responders to etanercept in the phase 3 reSURFACE 2 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.10.103 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB437

Keyword(s):

Severe Psoriasis ◽

Phase 3 ◽

Term Efficacy

Download Full-text

26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.496 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB119

Author(s):

Diamant Thaçi ◽

Christopher E.M. Griffiths ◽

Lars Iversen ◽

Andrea Peserico ◽

Ignasi Pau-Charles ◽

...

Keyword(s):

Severe Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Post Hoc Analysis ◽

Term Efficacy ◽

Post Hoc

Download Full-text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12046 ◽

2012 ◽

Vol 27 (12) ◽

pp. 1535-1545 ◽

Cited By ~ 109

Author(s):

A.B. Kimball ◽

K.A. Papp ◽

Y. Wasfi ◽

D. Chan ◽

R. Bissonnette ◽

...

Keyword(s):

Severe Psoriasis ◽

Term Efficacy ◽

The Phoenix

Download Full-text

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

British Journal of Dermatology ◽

10.1111/bjd.18232 ◽

2019 ◽

Vol 182 (3) ◽

pp. 605-617 ◽

Cited By ~ 18

Author(s):

K. Reich ◽

R.B. Warren ◽

L. Iversen ◽

L. Puig ◽

I. Pau‐Charles ◽

...

Keyword(s):

Clinical Trials ◽

Severe Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Term Efficacy ◽

Phase Iii Clinical Trials

Download Full-text

Long-term outcomes of ustekinumab in patients with moderate-to-severe psoriasis in a university hospital

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.730 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB179

Keyword(s):

Severe Psoriasis ◽

University Hospital ◽

Long Term Outcomes

Download Full-text

Long‐term efficacy and safety of ustekinumab for moderate‐to‐severe psoriasis: a 9‐year real‐life experience from a tertiary referral center in Turkey

Dermatologic Therapy ◽

10.1111/dth.15042 ◽

2021 ◽

Author(s):

Goncagül Babuna Kobaner ◽

Algün Polat Ekinci ◽

Armağan Kutlay

Keyword(s):

Life Experience ◽

Real Life ◽

Severe Psoriasis ◽

Efficacy And Safety ◽

Tertiary Referral ◽

Tertiary Referral Center ◽

Referral Center ◽

Term Efficacy

Download Full-text

Long-term efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 7 years in a real world setting: The experience of a reference Hospital in the Canary Islands

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.1048 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB233

Keyword(s):

Canary Islands ◽

Real World ◽

Severe Psoriasis ◽

Efficacy And Safety ◽

Term Efficacy ◽

Real World Setting ◽

Reference Hospital

Download Full-text

Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.734 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB181

Keyword(s):

Severe Psoriasis ◽

Term Efficacy

Download Full-text